## 3 Results  
### Clinical Evaluation of Treatment Efficacy  
From the year 2015 to 2018, a total of 50 patients (29 male and 21 female) with advanced non-squamous NSCLC received pemetrexed/platinum-based doublets chemotherapy. The median of age was 65 years old (range: 37 to 92 years old). Twenty-two of them harboured EGFR mutation and three of them were ALK positive. Chemotherapy regimens included 36 cisplatin and 14 carboplatin with pemetrexed, 13 of 50 patients combined with bevacizumab (Table 1).  
The initial response rate of chemotherapy included 26 partial responses, 12 stable diseases, and 10 progressive diseases. The treatment response rate and disease-control rate of pemetrexed/platinum doublet chemotherapy were 48.6% (18/37) and 75.7% (28/37), respectively. The treatment response rate and disease-control rate of bevacizumab-combined chemotherapy were 61.5% (8/13) and 92.3% (12/13), respectively (Table 1).  
\begin{table}
\begin{tabular}{l c c c} \hline \hline  & **Overall** & **PC (n = 37)** & **PCB (n = 13)** \\ \hline Age, years old, (median, range) & 65 (37–92) & 68 (37–92) & 62 (47–76) \\ Gender & & & \\ Male & 29 (58.0\%) & 25 (67.6\%) & 4 (30.8\%) \\ Female & 21 (42.0\%) & 12 (32.4\%) & 9 (69.2\%) \\ Smoking status & & & \\ Current or ever & 21 (42.0\%) & 18 (48.6\%) & 3 (23.1\%) \\ Never & 29 (58.0\%) & 19 (51.4\%) & 10 (76.9\%) \\ Mutation & & & \\ EGFR & 22 (44.0\%) & 16 (43.2) & 6 (46.2\%) \\ ALK & 3 (6.0\%) & 2 (5.4\%) & 1 (7.6\%) \\ Wild type & 25 (50.0\%) & 19 (51.4\%) & 6 (46.2\%) \\ Platinum & & & \\ Cisplatin & 36 (62.0\%) & 28 (75.7\%) & 8 (61.5\%) \\ Carboplatin & 14 (28.0\%) & 9 (24.3\%) & 5 (38.5\%) \\ Treatment Response & & & \\ PR & 26 (52.0\%) & 18 (48.6\%) & 8 (61.5\%) \\ SD & 14 (24.0\%) & 10 (27.0\%) & 4 (30.8\%) \\ PD & 10 (20.0\%) & 9 (24.3\%) & 1 (7.7\%) \\ Response rate (\%) & 52\% & 48.6\% & 61.5\% \\ Disease control rate (\%) & 80\% & 75.7\% & 92.3\% \\ \hline \hline \end{tabular} NSCLC: non-small cell lung cancer; PC: pemetrexed/platinum; PCB: pemetrexed/platinum/ bevacizumab; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; PR: partial response; SD: stable disease; and PD: progressive disease.  
\end{table}
Table 1: Pemetrexed plus platinum with and without bevacizumab for NSCLC: Basic Characteristics and Treatment Response.  
There was no significant difference of treatment response rate (RR) and disease-control rate (DCR) between pemetrexed/platinum doublet (PC) and bevacizumab-combined chemotherapy (PCB) (RR: \(p\) = 0.200 and DCR: \(p\) = 0.197, respectively). Patients treated with bevacizumab-combined chemotherapy had significant longer progression-free survival (PFS) and overall survival (OS) (PCB vs. PC, PFS, median, 15.4 vs. 7.7 months, \(p\) = 0.01; OS, median, 40.8 vs. 28.9, months, \(p\) = 0.02) (Figure 1).  
Figure 1: Kaplan–Meier survival analysis illustrated chemotherapy combination affects (**A**) progression-free survival (PFS) and (**B**) overall survival (OS). Non-small cell lung cancer (NSCLC) patients treated with bevacizumab-combined pemetrexed/platinum doublet chemotherapy (PCB) had significant longer PFS and OS compared to pemetrexed/platinum doublet (PC) (PCB vs. PC, PFS, median, 15.4 vs. 7.7 months, \(p\) = 0.01; OS, median, 40.8 vs. 28.9, months, \(p\) = 0.02).